{"prompt": "['Horizon Pharma USA, Inc.', 'Teprotumumab (HZN-001) IND: 112952', 'Date: 31 January 2019', 'Protocol: HZNP-TEP-302', 'Version 3.0, incorporating Protocol Version 2.1 and Amendment 2', 'The Sponsor has a legal responsibility to report fully to regulatory authorities all results of', 'administration of investigational drugs to humans. No investigational procedures other than those', 'described in this protocol will be undertaken on the enrolled subjects without the agreement of', 'the IRB/IEC and Sponsor.', '10 SOURCE DOCUMENTATION AND INVESTIGATOR FILES', 'The Investigator must maintain adequate and accurate records to document fully the conduct of', 'the study and to ensure that study data can be subsequently verified. These documents should be', 'classified in 2 separate categories: (1) Investigator study file and (2) subject clinical source', 'documents that corroborate data collected in the eCRFs. Subject clinical source documents', \"would include, as applicable, original hospital/clinic subject records; physicians' and nurses'\", 'notes; appointment book; original laboratory, ECG, electroencephalogram, radiology, pathology,', 'and special assessment reports; dispensing records; signed ICFs; consultant letters; and subject', 'screening and enrollment logs.', 'In order to comply with regulatory requirements, it is the policy of the Sponsor that, at a', 'minimum, the following be documented in source documents at the study center:', 'Medical history/physical condition and diagnosis of the subject before involvement in the', 'study sufficient to verify that the subject meets protocol entry criteria.', 'Study number, assigned subject number, and verification that written informed consent', 'was obtained (each recorded in dated and signed progress notes).', 'Progress notes for each subject visit (each dated and signed).', 'Records of each study visit including each study assessment and the identity of the staff', 'member performing the assessment.', 'Study drug dispensing and return.', 'Review by the Investigator or qualified personnel on the 1572 of laboratory test results.', 'Adverse events (start and stop date, description, action taken, and resolution).', \"Investigator or sub-investigator's signed assessment of each AE.\", 'Concomitant medications (start and stop dates, reason for use).', 'Condition of subject upon completion of, or premature withdrawal from, the study.', '11 CASE REPORT FORMS', 'An eCRF is required for every subject who signs the ICF. Required data must be entered on the', 'eCRF within the required time period, which will be outlined within each site agreement, after', 'PRIVATE AND CONFIDENTIAL INFORMATION OF HORIZON PHARMA USA, INC', 'Page 107 of 118']['Horizon Pharma USA, Inc.', 'Teprotumumab (HZN-001) IND: 112952', 'Date: 31 January 2019', 'Protocol: HZNP-TEP-302', 'Version 3.0, incorporating Protocol Version 2.1 and Amendment 2', 'data collection or the availability of test results. Separate source records are required to support', 'all eCRF entries. Data captured on the eCRF, and requested anonymized copies of supporting', 'documents, will be transferred to the Sponsor at study completion.', 'The Investigator will ensure that the eCRFs are accurate, complete, legible, and timely, and will', 'review and provide an electronic signature for the eCRF according to the standard operating', 'procedure of the CRO Data Management System. Final eCRFs will be provided to the', 'Investigator and Sponsor by CRO Data Management.', '12 STUDY MONITORING', 'The Investigator will ensure that the study is conducted in accordance with all regulations', 'governing the protection of human subjects. The Investigator will adhere to the basic principles', 'of GCP as outlined in Title 21 of the CFR, Part 312, Subpart D, \"Responsibilities of Sponsors', 'and Investigators\"; 21 CFR, Part 50, \"Protection of Human Subjects\"; 21 CFR, Part 56,', '\"Institutional Review Boards\"; 21 CFR, Part 54 \"Financial Disclosure by Clinical Investigators\";', 'and the ICH guideline entitled \"Good Clinical Practice: Consolidated Guidance\". Additionally,', 'this study will be conducted in compliance with the Declaration of Helsinki and with all local', 'laws and regulations.', 'The Investigator will ensure that all work and services described in, or associated with, this', 'protocol are conducted in accordance with the investigational plan, applicable regulations, and', 'the highest standards of medical and clinical research practice. The Investigator will provide', 'copies of the study protocol and IB to all Sub-Investigators, pharmacists, and other staff', 'responsible for study conduct.', 'All aspects of the study will be monitored by qualified individuals designated by the Sponsor.', 'The Sponsor will ensure that the study is monitored adequately in accordance with GCP', 'guidelines.', \"Prior to initiation of the study, the Sponsor's representatives will review with study center\", 'personnel information regarding the investigational drug, protocol requirements, monitoring', 'requirements, and reporting of SAEs.', 'At intervals during the study, as well as after the completion of subject enrollment, the study', 'center will be monitored by the Sponsor or designee for compliance. During these visits, the', 'masked monitor will discuss study progress, verify adherence to the protocol and the', 'completeness, consistency, and accuracy of the data being entered on the eCRF (source data', 'verification); oversee the resolution of outstanding data discrepancies, and check on various', 'aspects of study conduct (e.g., drug accountability, sample storage). The Investigator agrees to', 'allow unmasked monitors access to the clinical supplies, dispensing and storage areas, and', 'clinical records of the study subjects, and, if requested, agrees to assist the monitors. The', 'Investigator must cooperate with the monitors to ensure that any problems detected in the course', 'of these monitoring visits are resolved.', 'PRIVATE AND CONFIDENTIAL INFORMATION OF HORIZON PHARMA USA, INC', 'Page 108 of 118']\n\n###\n\n", "completion": "END"}